CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 20-929

CORRESPONDENCE

DUPLICATE



Eric Couture, Ph.D. Director, Regulatory Affairs

August 4, 2000

Robert Meyer, M.D., Director Division of Pulmonary Drug Products HFD-570 Room 10-B03 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857 RECO AUG - 7 2000

HFO-570

MANO RESERVE

Dear Dr. Meyer:

NDA 20-929 Pulmicort Respules™ (budesonide inhalation suspension) GENERAL CORRESPONDENCE: RESPONSE TO REQUEST FOR INFORMATION

Please refer to our Original NDA 20-929 for Pulmicort Respules submitted November 18, 1997, and our August 7, 1998 Resubmission. Please also refer to the Agency's May 20, 1998 and February 11, 1999 approvable letters, and to our February 9, 2000 response. Reference is also made to meetings with the Agency on March 25, December 9, 1999, March 7, July 27, and 31, and August 3, 2000. Please also refer to our May 9, July 31, and August 1, and 3, 2000 faxes, and to our June 9, and July 10, 2000 responses.

Reference is also made to our August 3, and 4, 2000 faxes, and a telephone request today from Dr. Poochikian for final specification sheets for the container closure components (Attachment 1). We are also providing as requested a copy of the unannotated package insert with all strengths; 0.25 mg/2mL, 0.5 mg/2mL, (Attachment 2), and a copy of the unannotated package insert for 0.25 mg/2mL and 0.5 mg/2mL strengths (Attachment 3). The labeling is also being provided electronically on a 3.5" diskette (Attachment 4).

An exact copy of the CMC information provided with this response is also being sent to the New England District Office.

I trust that the Agency will find this submission to be complete and acceptable in supporting the approval of the Pulmicort Respules (budesonide inhalation suspension) NDA.

Please direct any questions or requests for additional information to me at 610-695-1263 (fax 610-722-7784), or, in my absence, to James Sullivan, Regulatory Project Manager at 610-695-1423.

Sincerely,

Eric Couture, Ph.D.

Director, Regulatory Affairs

cc: Gretchen Trout (CDER)

1

Federal Express No.: 821988027650

cc: Richard Penta (New England District Office)

Federal Express No.: 821988027661

Attachment 2

4

Draft Labeling Page(s) Withheld

Attachment 3

____ Draft Labeling Page(s) Withheld



Eric Couture, Ph.D. Director, Regulatory Affairs

August 3, 2000

Robert Meyer, M.D., Director Division of Pulmonary Drug Products HFD-570 Room 10-B03 Center for Drug Evaluation and Research Food and Drug Administration 5600 Fishers Lane Rockville, MD 20857

REC'D

AUG: 4 2000

HFD-570

HFD-570

Dear Dr. Meyer:

NDA 20-929

Pulmicort Respules™ (budesonide inhalation suspension) AMENDMENT TO A PENDING APPLICATION

Please refer to our Original NDA 20-929 for Pulmicort Respules submitted November 18, 1997, and our August 7, 1998 Resubmission. Please also refer to the Agency's May 20, 1998 and February 11, 1999 approvable letters, and to our February 9, 2000 response. Reference is also made to meetings with the Agency on March 25, December 9, 1999, March 7, July 27, and 31, and August 3, 2000. Please also refer to our May 9, July 31, and August 1, 2000 faxes, and to our June 9, and July 10, 2000 responses.

Please find attached our Phase IV Commitments as discussed in our August 3, 2000 teleconference.

Labeling

AstraZeneca con	nmits to providing by February 1, 2001 (4 n	nonths post-launch) revised
packaging for Pu	lmicort Respules. This revision will replac	e the statement in the curren
foil and carton la	beling (Attachment 1) which reads '	
	with new wording, which will read "	
(Atta	chment 2).	

AstraZeneca plans to 3.25 mg and 0.5 mg presentations only. Therefore, we are providing two versions of the package insert and patient instructions: one containing all presentations (0.25 mg, 0.5 mg, and , and one containing the two presentations that will be used at launch.

Revisions to the package insert and patient instructions as discussed in the August 3, 2000 teleconference are also attached (Attachment 3). Per the Agency's request, the labeling attachments are provided electronically on CD-ROM.

Clinical

AstraZeneca commits to study and report by October 1, 2003, the effects of maintenance therapy with Pulmicort Respules at recommended doses in the indicated population (≥1 year of age) on the immunogenicity of a live virus vaccine (e.g., varicella).

CMC

Chemistry, Manufacturing and Controls Phase IV Commitments items 1-10 are attached (Attachment 4).

An exact copy of the CMC information provided with this response is also being sent to the New England District Office.

I trust that the Agency will find this submission to be complete and acceptable in supporting the approval of the Pulmicort Respules (budesonide inhalation suspension) NDA.

Please direct any questions or requests for additional information to me at 610-695-1263 (fax 610-722-7784), or, in my absence, to James Sullivan, Regulatory Project Manager at 610-695-1423, or Anita Sellers, CMC Manager at 610-695-1223.

Sincerely,

Eric Couture, Ph.D.

Director, Regulatory Affairs

Sent via facsimile

cc: Gretchen Trout (CDER)

Federal Express No.: 821988027098

cc: Richard Penta (New England District Office)

Federal Express No.: 821988027087

Enclosure: CD-ROM

Draft Labeling Page(s) Withheld



Memorandum of Facsimile Correspondence

Date:

August 3, 2000

To:

- Eric Couture

FAX:

610-722-7784

From:

Gretchen Trout

15/

Subject:

Pulmicort Respules

We are providing the attached information via telephone facsimile for your convenience, to expedite the progress of your drug development program. This material should be viewed as unofficial correspondence. Please feel free to contact me if you have any questions regarding the contents of this transmission.

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you received this document in error. please immediately notify us by telephone at (301) 827-1050 and return it to us at the FDA, 5600 Fishers Lane, HFD-570, DPDP, Rockville, MD 20857

Thank you.

As discussed at the teleconference this afternoon.

"AstraZeneca commits to study and report by October 1, 2003, the effects of maintenance therapy with Pulmicort Respules at recommended doses in the indicated population (≥1 year of age) on the immunogenicity of a live virus vaccine (e.g., varicella)."

APPEARS THIS WAY ON ORIGINAL

1

Page(s) Withheld

OFFICE OF DRUG EVALUATION II



TO: Eric Couture
Phone Number: 610-695-1263
Fax Number: 610-722-7784
FROM: Gretchen Trovt
DIVISION OF PULMONARY AND ALLERGY DRUG PRODUCTS
CDER Pulmonary Group (HFD-570), 5600 Fishers Lane Rockville, Maryland 20857
PHONE: (301) 827-1050 FAX: (301) 827-1271
Total number of pages, including cover sheet: 3 Date: 7-31-00
THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED

AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify us by telephone and return it to us at the above address by mail.

COMMENTS:

Thank you.

Page(s) Withheld



Memorandum of Facsimile Correspondence

Date:

July 19, 2000

To:

Eric Couture, Ph.D.

Director, Regulatory Affairs

FAX:

610-722-7784

From:

Gretchen Trout

15/

Subject:

Labeling comments for NDA 20-929

We are providing the attached information via telephone facsimile for your convenience, to expedite the progress of your drug development program. This material should be viewed as unofficial correspondence. Please feel free to contact me if you have any questions regarding the contents of this transmission.

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you received this document in error, please immediately notify us by telephone at (301) 827-1050 and return it to us at the FDA, 5600 Fishers Lane, HFD-570, DPDP, Rockville, MD 20857 Thank you.

23

_ Draft Labeling Page(s) Withheld

cc:

NDA 20-929

Div. File

HFD-570/Trout

HFD-570/Purucker

HFD-570/Meyer

HFD-570/Sun

HFD-570/Kim

HFD-570/Poochikian

HFD-570/Choi

HFD-570/Uppoor

HFD-570/Wilson

Drafted: GST/July 11, 2000/n:\staff\troutg\20929fax

Initialed by:

Choi/7-11-00

Uppoor/7-11-00

Wilson/7-17-00

Kim/7-18-00

Purucker/7-19-00

Meyer/7-19-00

Sun/7-19-00

CORRESPONDENCE

TROUT

RECORD OF TELEPHONE CONVERSATION

Date: Project Manager:	June 19, 2000 Hilfiker		
Subject: NDA:	Proposed Specifical 20-929	tions for Incoming Materials	
Sponsor:	AstraZeneca		
Product Name:		(budesonide inhalation solution)	
applicant was issued an app	rovable (AE) action on tion letter on February	nicort Respules on November 18, 1997. The February 11, 1999. AstraZeneca submitted a 9, 2000. The PDUFA due date for this	
During a March 7, 2000, tell for the container-closure system	based upon	nested that AstraZeneca submit specifications, of components of	f
AstraZeneca proposed subm 2000, for review prior to the	nission of the caction. If the NDA is	and specifications by July 10, otherwise able to be approved by August 10	
	itment to submit specifi	AstraZeneca requested that FDA approve the ications with supportive data for no)
the approvability of the ND	A without reviewing that and specifications as	Zeneca that the Division would not commit to de data. The acceptability for s a Phase 4 commitment will depend on the	
	ary and Allergy Drug Pr	with Guirag Poochikian, CMC Team Leader roducts, to clarify the information that will be	
FDA Participants:	David Hilfiker Guirag Poochikian	Project Manager CMC Team Leader, DNDC II	
AstraZeneca Participant:	Eric Couture	Regulatory Affairs	
data, as has been has not previously allowed	en communicated previous competitors to submit to very least, AstraZene	nmit to approval prior to submission of the ously by Ms. Trout. Furthermore, the Division profiles and specifications as a seca will need to establish acceptance criteria data prior to approval.	n

July 10, 2000, submission.
AstraZeneca remains interested in a Phase 4 commitment to provide
data and specifications post-approval.
Dr. Poochikian emphasized that FDA may not allow — data to be submitted as a Phase 4
commitment if the do not assure FDA that there is minimal risk in
approving the drug product without the data. If AstraZeneca decides to pursue
approval in the absence of data, they are assuming a large risk and should not blame
the FDA if approval is withheld due to the results and absence of data.
Dr. Couture acknowledged that AstraZeneca assumes the risk in this proposal and will defer to
FDA's decision based on the data.

Dr. Couture mentioned that one additional item will be included in the June 9 submission to FDA. AstraZeneca will be proposing to alter the specification for MMD (particle size) based on further data generated from the analysis of batches. (The previous specification was proposed based on based on batches.) AstraZeneca will not propose widening the specification, but rather shifting the specification range. Dr. Poochikian stated that the proposal sounds reasonable, but will depend on the supportive data.

David Hilfiker Pjoject Manager 5/ 6/26/00

Cc:

Original NDA 20-929 HFD-570/Division file HFD-570/Hilfiker HFD-570/Trout HFD-570/Kim HFD-570/Poochikian/6-23-00

C:\my_documents\N20929\000616tel

20929

MINUTES OF TELECONFERENCE

AstraZeneca NDA 20-929 Pulmicort Respules May 22, 2000

FDA REPRESENTATIVE

Gretchen Trout, Project Manager

SPONSOR REPRESENTATIVE

Eric Couture, Regulatory Affairs

BACKGROUND: On March 7, 2000, representatives from the Division and AstraZeneca held a teleconference to discuss outstanding chemistry deficiencies for this NDA. AstraZeneca submitted a facsimile on May 9, 2000 (see attached) with their proposed plan of action to respond to the Division's requests for information.

Following an internal meeting to discuss the May 9, 2000, facsimile I telephoned Dr. Couture to inform him of the following.

The Division will not commit to the approvability of AstraZeneca's proposed response; however, the more data they can provide us as early as possible, the more likely they will be able to obtain a favorable action. The Division agrees to the submission of specific data by June 9, 2000, and by July 10, 2000. Whether or not we will agree to a Phase 4 commitment to provide the remaining data in October (i.e, following approval), will depend on the data submitted by July 10, 2000.

I also informed Dr. Couture that the Division intends to proceed with labeling negotiations so that we can be prepared for an approval action. This does not mean that AstraZeneca will receive approval this cycle.

Dr. Couture indicated that he understood.

15/

Gretchen Trout Project Manager



Fax

To

שם: כנ שטיינט- יבול

Gretchen Trout, Project Manager

Fax number

301-827-1271

Company

Pulmonary Division, CDER

From

Jim Sullivan

Fax number

610-722-7784

Date

Regulatory Project Manager May 9, 2000; 14:55

Total pages

1 (💡)

om bedee '(1

Including cover

Subject

General Correspondence: Response to FDA Request for Information

CONFIDENTIAL

Dear Gretchen:

Please refer to our NDA 20-929 for Pulmicort Respules™ (budesonide inhalation suspension), and the February 9, 2000 response to the Agency's February 11, 1999 approvable letter. Reference is also made to the March 7, 2000 teleconference where the Agency requested additional information on Please find attached a draft proposed plan of action to respond to the Agency's request for information.

Please forward this information to Dr. Poochikian and Dr. Kim. I welcome the opportunity to have a brief discussion with Dr. Poochikian and/or Dr. Kim to discuss the proposed plan and timing.

Please direct any questions or requests for additional information to me at 610-695-1263 (fax no. 610-722-7784), or in my absence, to James Sullivan, Regulatory Project Manager, at 610-695-1423.

Sincerely,

Eric Couture, Ph.D

E. Cont

Director, Regulatory Affairs

AstraZeneca L.P. 725 Chesterbrook Blvd Wayne, PA 19087

Tel +1 610 695 1000



NDA 20-929 Pulmicort Respulcs (budesonide inhalation suspension)

.

AstraZeneca proposes the following strategy and timelines to address the Agency's request for additional information during the 7 March 2000 teleconference. Reference is made to item numbers per the 9 February 2000 submission.

AstraZeneca commits to provide by 9 June 2000:				
Response to Item 3c:				
	· · · · · · · · · · · · · · · · · · ·			
Response to Item 4:				
· Updated DMF authorization le	etters			
• The appropriate DMF contact; Agency as requested.	persons and fax numbers have been provided to the			
In addition Stability reflecting Respule	ng storage through at 25°C/40% RH in new will be provided.			
	f Contents for this submission is provided on the			
following page:	·			
	. <u>-</u> *			

	ROPOSED TABLE OF CONTENTS FOR 9 JUNE 200	M 20RWIZZIÓN	PA
	Annual Commence of the Commenc		
	,	***********************	
		wer-	
		-	
•	^	•***	
L	DMF AUTHORIZATION LETTERS		
á	STABILITY STUDY		
	Stability Report	***************************************	

Page(s) Withheld

Memorandum of Telephone Facsimile Correspondence

Date:

May 15, 2000

To:

Eric Couture, Ph.D.

Fax:

610-722-7784

From:

Gretchen Trout

Project Manager

Subject:

NDA 20-929

March 7, 2000 teleconference

Reference is made to the teleconference held between representatives of your company and this Division on March 7, 2000. Attached is a copy of our final minutes for that teleconference. These minutes will serve as the official record of the teleconference. If you have any questions or comments regarding the minutes, please call me at (301) 827-1058.

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you received this document in error, please immediately notify us by telephone at (301) 827-1050 and return it to us at FDA, 5600 Fishers Lane, HFD-570, DPDP, Rockville, MD 20857.

Thank you.

APPEARS THIS WAY ON ORIGINAL

INDUSTRY TELECONFERENCE MINUTES

DATE: March 7, 2000

NDA: 20-929

PRODUCT: Pulmicort Respules (budesonide nebulizing suspension)

SPONSOR: AstraZeneca

FDA PARTICIPANTS:

Chong-Ho Kim, Chemistry Reviewer Guirag Poochikian, Chemistry Team Leader Gretchen Trout, Project Manager

SPONSOR PARTICIPANTS:

Eric Couture, Director, Regulatory Liaison Jim Sullivan, Regulatory Affairs

BACKGROUND: The Division requested this teleconference to discuss Astra's submission dated February 9, 2000, containing responses to the Division's February 11, 1999, approvable (AE) letter. NOTE: the numbers and letters refer to the Division's comments from the AE letter, and Astra's corresponding responses.

The Division informed Astra that we are reviewing their amendment, and there are still some deficiencies. They are as follows.

3.a.	Provide compositions of the there are other components in the we want all of the components in contact with the product.	 For example, omponents not just
3.c.	Provide acceptance criteria and test methods for	

Acceptance criteria should be modified to reflect the observed data. The Division referenced tables 8, 9, and 10.

- 4. DMFs were reviewed and found inadequate. The Division will issue deficiency letters this week. The DMF holders should respond as quickly as possible.
- 6.b. Astra's proposed limits are too high. USP standards are not intended for inhalation dosage forms. This is very important. We need procedural information: time, temperature, duration, etc.

ADDITIONAL INFORMATION

Astra questioned if the Division could comment on the expiry and the foil labeling. The Division replied that we cannot comment on that because the nay effect the expiration dating period. We will not comment until we have all of the data.

Gretchen Trout

Project Manager

Cc: Orig. NDA 20-929

Div. File

HFD-570/Kim

HFD-570/Poochikian

HFD-570/Trout

Drafted: GST/March 23, 2000

Rd initial by: Kim/April 3, 2000 File name: 20929tel

MINUTES/CORRESPONDENCE

APPEARS THIS WAY. ON ORIGINAL

FEB 2 3 2000

NDA 20-929

AstraZeneca 725 Chesterbrook Blvd. Wayne PA, 19087-5677

Attention: Eric Couture, Ph.D.

Director, Regulatory Affairs

Dear Dr. Couture:

We acknowledge receipt on February 10, 2000, of your February 9, 2000, resubmission to your new drug application (NDA) for Pulmicort Respules (budesonide inhalation suspension).

This resubmission contains additional chemistry, manufacturing, and controls information submitted in response to our February 11, 1999, action letter.

We consider this a complete class 2 response to our action letter. Therefore, the user fee goal date is August 10, 2000.

If you have any questions, call me at (301) 827-1058.

Sincerely yours,

15/

Gretchen Trout
Project Manager
Division of Pulmonary and Allergy Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc:

Archival NDA 20-929

HFD-570/Div. Files

HFD-570/G.Trout

HFD-570/Kim

HFD-570/Poochikian

HFD-570/Purucker

HFD-570/Meyer

HFD-570/Uppoor

HFD-570/Sun

HFD-570/Wilson

HFD-570/Elashoff

DISTRICT OFFICE

Drafted by: GST/February 22, 2000

Initialed by: Jani/2-22-00

final: Trout/2-23-00

filename: n:\staff\troutg\20929c2

CLASS 2 RESUBMISSION ACKNOWLEDGEMENT (AC)

(DDR: Update the user fee goal date based on the class of resubmission.)

APPEARS THIS WAY
ON ORIGINAL

Astra USA, Inc. P.O. Box 4500 Westborough, MA 01581-4500

Attention: Dennis Bucceri

Vice President Regulatory Affairs

Dear Mr. Bucceri:

We acknowledge receipt on August 11, 1998, of your August 7, 1998, resubmission to your new drug application (NDA) for Pulmicort Respules (budesonide inhalation suspension), 0.25 and 0.5 mg.

This resubmission contains additional information submitted in response to our May 20, 1998, action letter.

We consider this a complete class 2 response to our action letter. Therefore, the user fee goal date is February 11, 1998.

If you have any questions, contact Mr. David Hilfiker, Project Manager, at (301) 827-1046.

Sincerely yours,

15

Cathie Schumaker, R.Ph.
Chief, Project Management Staff
Division of Pulmonary Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

cc:

Archival NDA 20-929 HFD-570/Div. Files HFD-570/Hilfiker HFD-570/Schumaker/9-9-98 HFD-570/Trout DISTRICT OFFICE

Drafted by:

HFD-570/Hilfiker/9-8-98

final: filename:

HFD-570/Hilfiker/9-10-98 c:\my_documents\n20929\98-09-08.acltr/doc

ACKNOWLEDGEMENT (AC)

⊃/ _____/

151 Hq-10-98

9/13/97

APPEARS THIS WAY ON ORIGINAL



Memorandum of Telephone Facsimile Correspondence

Date:

April 21, 1998

To:

Dennis Bucceri

Vice President, Regulatory Affairs

FAX # 508-836-8390

From:

Gretchen Trout

" B

Project Manager

15]

Through:

Cathie Schumaker

Chief, Project Management Staff

Subject:

Pulmicort Respules


We are providing the attached information via telephone facsimile for your convenience, to expedite the progress of your drug development program. This material should be viewed as unofficial correspondence. Please feel free to contact me if you have any questions regarding the contents of this transmission.

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you received this document in error, please immediately notify us by telephone at (301) 827-1050 and return it to us at the FDA, 5600 Fishers Lane, HFD-570, DPDP, Rockville, MD 20857

Thank you.

Please refer to your pending November 18, 1997, new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug and Cosmetic Act for Pulmicort Respules (budesonide nebulizing suspension) 0.25, 0.5 mg.

The following requests for information are with regard to microbiology issues identified during review of your NDA.



3. Does the drug product suspension support microbial growth?

If you have any questions, please contact Ms. Gretchen Trout, Project Manager, at (301) 827-1058.

cc: Orig. NDA 20-929 Div. File

HFD-570/Kim

HFD-570/Poochikian

HFD-570/Trout

HFD-805/N. Sweeney

drafted: GST/April 20, 1998/n:\staff\troutg\20929.2fax

CORRESPONDENCE

FAX



FROM	DATE	
Murad Husain	4/23/98	
DEPARTMENT	FAX NO.	
Regulatory Affairs	(508) 836-8390	
TO	FAX NO.	
Gretchen Trout	(301) 827-1271	
Division of Pulmonary Drug Products		
SUBJECT	PAGES	
NDA 20-929/Pulmicort Respules	1(2)	

Dear Gretchen,

As follow-up to our phone conversation on Monday, May 20, 1998, below is a list of questions seeking clarification of some of the CMC comments from the Division's 4/15/98 letter.

Per your request, this fax also provides our response to Dr. Brad Gillespie's question from April 7, 1998 regarding "n.e." (not existing) entries on the Table of Investigational Formulations - Pharmacokinetic Studies.

CMC:

We would like clarification of the Division's following comments (numbers correspond to that of the Division's letter of April 15, 1998):

Comments 5.b.: Is the Division's recommendation for the specifications of particle size of the drug product based on the initial batch analysis data (e.g., Certificates of Analyses) or the stability data? We ask this question, because the stability data does not support the recommended specifications.

Comment 11.: To				namely		
	the primary	stability ba	tches of the	drug produc	t were packaged i	V *****
from these two so	urces. The st	ability data	collected fr	om the drug	product packaged	l with
!		was provid	ded in the or	iginal NDA	Volume 1.007, pag	ze 7.
Item 3.B.9.a unde	r Primary Sta	bility Data	and page 26	63 (page 268	in PDF), Item 3.B.	9.b.10
under Special Sta	oility Studies	s. Please cla	rify the Divi	ision's comm	ien <u>t</u>	
			=			

MAIUNG ADDRESS:
Astra USA, Inc.
P.O. Box 4500
Westborough, MA 01581-4500

OFFICE: 50 Otis Street Westborough, MA

TEL: 508-366-1100

FAX: 508-366-7406

TELEX:

6810105-Cable/Astropharm

FROM	DATE	PAGES
Murad Husain	4/23/98	2(2)

Comment 14.: This comment is not clear. Please note that, the drug product specifications for the test to be performed during stability study, which are listed on the proposed stability protocol, and the corresponding specifications listed on the drug product Specifications submitted under NDA item 3.B.7.a., are the same.

Comment 18.: Please clarify what the Division meant by "appropriate studies need to be performed to qualify the Study was submitted in the original NDA Volume 1:007, page 260 (page 265 in PDF), Item 3.B.9.b.9. under Special Stability Studies.

Investigational Formulation - Pharmacokinetic Studies:

Response to Dr. Brad Gillespie's question regarding the "n.e" entries in the table for the Investigational Formulations - Pharmacokinetic Studies in Volume 1.17, page 59 (telephone contact dated 4/7 and 4/14/98) are as follows:

Please call me at (508) 836-8403 for additional information and clarification.

Sincerely With Chistian 1-

Murad Husain Associate Director

Regulatory Affairs

Astra USA, Inc. P.O. Box 4500 Westborough, MA 01581-4500

Attention: Dennis Bucceri Vice President Regulatory Affairs

Dear Mr. Bucceri:

Please refer to your pending November 18, 1997, new drug application submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Pulmicort Respules (budesonide inhalation suspension) 0.25 mg, 0.5 mg, and 1.0 mg.

We also refer to your amendment dated January 15, 1998.

We have completed our review of the Chemistry, Manufacturing, and Controls section of your submission and have identified the following deficiencies.

The following comments pertain to the proposed drug product specifications and test methods.

1.	The proposed specification for s not justified; the				
•	specification should be significantly tightened to reflect the observed data. In				
	addition, a relationship of the proposed to a certain reference standard should be established.				
2.	The method for 'should indicate'				
	viewed. In addition, the proposed specification should be tightened to reflect actual data and there should be an upper limit; e.g., NMT				
3.	The following comments pertain to the specification and test method for				
J.	Edetate Disodium Dihydrate.				
	a. The retention time target of , is too close to the We recommend that the target retention time be				
	increased to greater than				

	b.	Please provide information about the observed levels) found in method		
	c.	Please state whether any other		
*				
	d.	The proposed specification does not reflect the stability data. The specification should be tightened to		
4.	reflect test n	content uniformity specification should be clearly spelled out and be ctive of the data of multiple batches. Moreover, the content uniformity nethod should be described in detail. An appropriate method number or dedure number should be assigned.		
5.	The following comments pertain to the specifications and test m "Particle Size of Budesonide Micronized API and Budesonide Ir Suspensions by			
	a.	Please provide reproducibility data and the reports		
		which were referenced in the validation studies. In addition, provide particle size distribution analysis printouts of different batches.		
	b.	Batch analysis data indicate that the proposed specifications should be significantly tightened; e. g.,		
	• .	MMD:		
	•	d < NLT		
		d < /		
		d < manufacture NMT resource		
6.	The fo	ollowing comments pertain to the impurities and degradation products.		
	a.	The specifications should be tightened to reflect the stability data as follows:		
		Total: NMT NMT NMT Individual unspecified impurity: NMT		
		Total unspecified impurity: NMT —		

b. The LODs and LOQs for degradation products are too high. We strongly recommend that the analytical method be improved.

The following comments pe	ertain to	manufacturing.
---------------------------	-----------	----------------

lease provide information (composition and compatibility with the formulation components) on the sused for manufacturing. comments pertain to the container and closure system. The application should include references to authorized drug master files DMFs) for each of the The information should include complete compositions, sources, acceptance/release criteria, test methods, data, etc. The application should contain compositions, appropriate acceptance pecifications, test methods and data for each of the packaging components
The information should include complete ompositions, sources, acceptance/release criteria, test methods, data, etc. the application should contain compositions, appropriate acceptance pecifications, test methods and data for each of the packaging components
OMFs) for each of the The information should include complete ompositions, sources, acceptance/release criteria, test methods, data, etc. The application should contain compositions, appropriate acceptance pecifications, test methods and data for each of the packaging components
pecifications, test methods and data for each of the packaging components
once the suppliers' test results are confirmed through multiple batches using a perception of packaging components may be accepted based on Certificates of Analysis (COAs) from the supplier. In the latter case, the results of COAs should be periodically alidated on a preset schedule.
quivalency of secondary packaging from different sources should be stablished, documented, and data submitted in terms of
he following comments pertain to the

į

21.

The following comments pertain to the drug product stability. 13. The stability protocol provided does not contain a specification and test for This parameter should be a part of the stability protocol. Acceptance criteria for stability should be the same as those for drug product 14. specifications on shelf-life. 15. It is stated that since there was some difficulty in of storage; Pulmicon Respules are recommended to be stored "upright". Please provide an explanation for the cause of the - problem. 16. Please provide information (nature, extent, etc.) about the found in samples stored for ____at 40°C/30% RH (Table 32, page 100, vol. 1.7). What will be the impact at Please also provide the detection method for the 17. , study between was reported. A study of condition and its impact on the particle size distribution. is recommended (see comment 16. above). 18. Appropriate studies need to be performed to qualify the used for recommended. Please also refer to comments 9, and 10, above. 19. The stability commitment and protocols should be updated; accelerated stability should be added to the protocol. 20. It is stated that deviations that do not affect the safety and efficacy of the product will be promptly discussed with the FDA's District Office according to 21 CFR 314.81(b)(1)(ii) in the post approval stability commitment (page 305, vol. 1.7). A statement "stability failures will also be discussed with the

The following comment pertains to the Environment Assessment.

review division" should be added to the paragraph.

Updated stability data and protocol should be provided.

24.

22. Regarding a request for categorical exclusion of environmental assessment, please provide actual calculations which should include all the budesonide containing products for the estimated concentration of the drug substance at the point of entry into the aquatic environment.

The following preliminary comments pertain to the labeling.

23.	The established name should be revised to "budesonide inhalation
	suspension."

25.	The fact that the		
		A CONTRACTOR OF THE PROPERTY O	(See
	comment 18 above	o)	

The tab portion of each unit should be extended/enlarged to allow

We would appreciate your prompt written response so we can continue our evaluation of your NDA. Please note, however, that while we are providing these comments to you at this time in order to allow you as much time as possible to address them, providing a response to these comments will not necessarily preclude the issuance of an action letter. You are encouraged to contact this Division for assistance in addressing the above issues.

If you have any questions, please contact Ms. Gretchen Trout, Project Manager, at (301) \$27-1050.

Sincerely yours,

Guirag Poochikian, Ph.D.
Chemistry Team Leader, DNDC II
Division of Pulmonary Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

NDA 20-929
Page 6
cc:
Original NDA 20-929
HFD-570/Div. Files
HFD-570/CSO/G.Trout
HFD-570/Kim
HFD-570/Poochikian
HFD-820/ONDC Division Director (only for CMC related issues)

Drafted by: GST/April 9/1998/n:\staff\troutg\20929.let

Initialed by: Schumaker/4-10-98

Kim/4-13-98

Schroeder (for Poochikian)/4-14-98

final: Trout/4-15-98

INFORMATION REQUEST (IR)



Memorandum of Telephone Facsimile Correspondence

Date:

January 30, 1998

To:

Dennis Bucceri

Vice President, Regulatory Affairs

FAX # 508-836-8390

From:

Gretchen Trout

15/

Project Manager

Subject:

Pulmicort Respules

We are providing the attached information via telephone facsimile for your convenience, to expedite the progress of your drug development program. This material should be viewed as unofficial correspondence. Please feel free to contact me if you have any questions regarding the contents of this transmission.

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE

LAW. If you are not the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you received this document in error. please immediately notify us by telephone at (301) 827-1050 and return it to us at the FDA, 5600 Fishers Lane, HFD-570, DPDP, Rockville, MD 20857

Thank you.

Please refer to your pending November 18, 1997, new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug and Cosmetic Act for Pulmicort Respules (budesonide nebulizing suspension) 0.25, 0.5 and mg.

To assist us in our review of the clinical pharmacology and biopharmaceutics section of your submission, we request that you provide the following information.

- pmol, not in units of concentration. It appears that in some cases, of plasma were used and in others, mL. Thus, it is difficult to interpret assay performance data. All assay validation data should be converted to pmol/L.
- 2. Data to describe variability at the individual points of the standard curve were not included. Individual standard curve data should be provided, including all calculated plasma concentration values. Additionally, descriptive estimates of mean, maximum, minimum and %CV should be included for all standard concentrations.

We would appreciate your prompt written response so we can continue evaluation of your NDA.

1

If you have any questions, please contact me at (301) 827-1058.

APPEARS THIS WAY ON ORIGINAL

Orig. NDA 20-929 Div. File HFD-570/Gillespie HFD-570/Trout

drafted: GST/January 30, 1998/n:\staff\troutg\20929.2fax

Schumaker/ 15/ 13/97 Gillespie/ 15/ 1/20/44 rd initial by:

CORRESPONDENCE



Memorandum of Telephone Facsimile Correspondence

Date:

January 16, 1998

To:

Dennis Bucceri

Vice President, Regulatory Affairs

FAX # 508-836-8390

From:

Gretchen Trout

15 /

Project Manager

Subject:

Pulmicort Respules

We are providing the attached information via telephone facsimile for your convenience, to expedite the progress of your drug development program. This material should be viewed as unofficial correspondence. Please feel free to contact me if you have any questions regarding the contents of this transmission.

THIS DOCUMENT IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND PROTECTED FROM DISCLOSURE UNDER APPLICABLE LAW. If you are not the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you received this document in error, please immediately notify us by telephone at (301) 827-1050 and return it to us at the FDA, 5600 Fishers Lane, HFD-570, DPDP, Rockville, MD 20857

Thank you.

Please refer to your pending November 18, 1997, new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug and Cosmetic Act for Pulmicort Respules (budesonide nebulizing suspension) 0.25, 0.5 and mg.

To assist us in our review of the pharmacology and toxicology section of your submission, we request that you provide your justification for conducting the 3-month toxicity study (study No. 97058-1) in dogs aged 5 to 6 weeks for the proposed pediatric population

We would appreciate your prompt written response so we can continue evaluation of your NDA.

If you have any questions, please contact me at (301) 827-1058.

APPEARS THIS WAY ON ORIGINAL

cc: Orig. NDA 20-929 Div. File

HFD-570/Tripathi HFD-570/Trout

drafted: GST/January 14, 1998/n:\staff\troutg\20929.fax

rd initial by: Schumaker/1-13-98

Tripathi/1-14-98 /Sun/1-15-98

CORRESPONDENCE

APPEARS THIS WAY ON ORIGINAL

DEC 1 9 1997

NDA 20-929

Astra USA, Inc. P.O. Box 4500 50 Otis Street Westborough, MA 01581

Attention: Dennis Bucceri

Vice President Regulatory Affairs

Dear Mr. Bucceri:

We have received your new drug application (NDA) submitted under section 505(b) of the Federal Food, drug, and Cosmetic Act for the following:

Name of Drug Product: Pulmicort Respules (budesonide

nebulizing suspension), .25 mg, 0.5

mg,

Therapeutic Classification: P

Date of Application: November 18, 1997

Date of Receipt: November 20, 1997

Our Reference Number: NDA 20-929

Unless we notify you within 60 days of the receipt date that the application is not sufficiently complete to permit a substantive review, this application will be filed under section 505(b) of the Act on January 19, 1998, in accordance with 21 CFR 314.101(a).

Under 21 CFR 314.102(c) of the new drug regulations you may request an informal conference with this Division (to be held approximately 90 days from the above receipt date) for a brief report on the status of the review but not on the application's ultimate approvability. Alternatively, you may choose to receive such a report by telephone. -Should you wish a conference, a telephone report, or if you have any questions concerning this NDA, please contact Ms. Gretchen Trout, Project Manager, at (301) 827-1058.

NDA 20-929 Page 2

Please cite the NDA number listed above at the top of the first page of any communications concerning this application.

Sincerely yours,

Cathie Schumaker
Chief, Project Management Staff
Division of Pulmonary Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

APPEARS THIS WAY ON ORIGINAL

NDA 20-929 Page 3

cc: Orig. NDA 20-929 Div. File

HFD-570/Trout

HFD-570/Chu

HFD-570/Meyer

HFD-570/Elashoff

HFD-570/Wilson

HFD-570/Tripathi

HFD-570/Sun

HFD-870/Gillespie

HFD-870/Chen

HFD-570/Kim

HFD-570/Poochikian

Drafted by: _GSTrout/Dec. 11, 1997/n:\staff\troutg\20929.let

Final Typed by: LGrimshaw/12-17-97

ACKNOWLEDGEMENT (AC)

APPEARS THIS WAY ON ORIGINAL

TROUT

INDUSTRY MEETING MINUTES

Astra
NDA 20-929
Pulmicort Respules (budesonide inhalation suspension)
December 9, 1999

FDA REPRESENTATIVES

Chong-Ho Kim, Chemistry Reviewer
Bob Meyer, Division Director
Guirag Poochikian, Chemistry Team Leader
Mary Purucker, Medical Reviewer
Gretchen Trout, Project Manager

SPONSOR REPRESENTATIVES

Diane Alelva, Director, Product Industrialization
Bertil Andersson, Global Product Director, Pulmicort
Frank Casty, Global Medical Leader
Eric Couture, Director, Regulatory Liaison
Mario Cruz-Rivera, Director, Drug Development
Donna Dea, Respiratory Therapeutic Area Regulatory Leader
John Lally, Leader, Product Certification
Cheryl Larrivee-Elkins, Leader, Manufacturing Technical Services
Robert Monaghan, Senior Regulatory Project Manager
Jessica Sjunnesson, Responsible Pharmacist, AstraZeneca R&D
Thomas Lööf, Pharmaceutical Project Leader

BACKGROUND: Astra requested this meeting to discuss the issue of in the Pulmicort Respules. Reference is made to the submission dated November 15, 1999. Reference is also made the facsimile dated December 8, 1999 (see attachment 1) regarding dispensed dose.

Astra indicated that their response to the Agency's February 11, 1999, approvable letter is complete with the exception of responding to the issue of

Astra made a presentation (see attachment 2) showing what tests were conducted and the resulting data collected. The shaded areas in the tables indicate new data not previously submitted to the Agency.

Astra explained the various testing done and provided some clarifications.

VISUAL INSPECTION: respule strips were randomly selected from each lot, and all were visually inspected. For the visual inspection, the inspectors just indicated whether or not were seen, the were not counted. Inspectors were pre-qualified to detect

MICROSCOPIC: During the microscopic evaluation, one respule per strip was evaluated and the were counted. The data on tables 4 and 5 are from microscopic evaluations and the number of respules evaluated were made up of the 9 controls plus all of those respules identified visually (see table 2) as having

DISPENSED DOSE (data from the December 8, 1999, facsimile) was collected by taking 5 respules from a strip and dispensing each one individually into its own container. Each respules was analyzed separately. The data from this lot (1990902702) is atypical and this lot is on stability. The previous — loss in dose was corrected with the new respule design (a respule with decreased headspace).

DROPLET SIZE DISTRIBUTION (graph) shows data from three respules with visual , and three without. A LC Parijet Plus nebulizer with a flow rate of 28.2 was used. Astra stated that statistically there was no difference in droplet size distribution between the respules with ______, and those without.

All the data are from lots manufactured at the United States Westboro facility (this is the only facility that can manufacture sterilized budesonide).

Particles of less than — are not specifically controlled, however, particles of this size are always seen in clusters. The Division stated that it would be appropriate to have a complete profile on the size and numbers of ______ including the ____ range. Astra replied that it is very difficult to measure the _____ range. The Division questioned how the current respules compare to the clinical batches with regard to ______ in the ____ range. Astra replied that they will discuss this internally.

The Division feels that Astra has enough data to develop a fixed, final specification. Astra should include the specification in their response to the approvable letter. Astra stated that they would like to collect their database overtime to see what is happening so that they can distinguish atypical batches. However, they can consider shortening their original proposal of two years stability data. The Division replied that by the time of approval we would like to be as close to a final specification as we can get, the specifications can be changed later, if necessary, with a prior approval supplement.

With regard to dispensed dose, the Division pointed out that the 0.25 mg product has the least number of _____ and yet is the most prone to problems with loss of dose. Astra may need to treat the 0.25 mg product individually (currently they average all _____ strengths). Astra stated that they do not have a dispensed dose specification, however they do have dispensed dose data. In general _____ of the dose is dispensed and they have not seen a difference between the batches with _____ and those without.

CONCLUSIONS:

- 1. The Division cannot discuss acceptance criteria until the data are reviewed.
- 2. Particle size distribution needs to be controlled.
- 3. The Division will consider whether controls should be on individual respules or on a mean.
- 4. It may be more appropriate to have separate specifications for the different strengths.

Gretchen Trout, Project Manager

Attachment 1

APPEARS THIS Part ON OTHER



Fax

To

Ms. Gretchen Trout

Project Manager

Company

Pulmonary Division

From

Dr. Eric Couture

Date

8 December, 1999; 15:44

Subject

Response to FDA Request

Fax number

301-8271271

610-722-7784 Astra

301-897-2559 Marriott

Total pages

Dear Ms. Trout:

Please refer to your request today for clarification on dispensed dose for Pulmicort Respules (budesonide inhalation suspension).

Please call if you have any further questions.

Sincerely yours,

Eric Couturo, Ph.D

Director, Regulatory Llaison

AstraZeneca L.P. 725 Chesterbrook Blvd Wayne, PA 19087

+1 610 695 1000